Navamedic

Navamedic ASA: Appointment of CFO

Oslo, 8 December 2025: Navamedic ASA ("Navamedic" or the "Company", OSE ticker:

"NAVA") is pleased to announce that the Company has appointed Nils Ole Krekling

Chief Financial Officer (CFO) of Navamedic ASA, effective 1 January 2026.

Mr. Krekling joins Navamedic from Kongsberg Gruppen ASA, where he currently

serves as Group VP Corporate Development and Head of M&A.

"With extensive experience from both finance and strategy roles, Mr. Krekling

brings valuable expertise that will strengthen our financial leadership and

support our strategic ambitions," says Kathrine Gamborg Andreassen, CEO of

Navamedic.

"I am pleased to join Navamedic as CFO. Navamedic is a well-established

organization with bold ambitions, and I look forward to joining the team and

contributing to the Company's continued financial performance and strategic

development," says Nils Ole Krekling.

For further information, please contact:

Kathrine Gamborg Andreassen, CEO, Mobile: +47 951 78 680 E-mail:

About Navamedic

Navamedic ASA is a Nordic pharmaceutical company dedicated to enhancing people's

quality of life by being a reliable supplier of high-quality prescription,

consumer health, and hospital products to hospitals and pharmacies. Our growing

product portfolio has been carefully selected to meet current public health

concerns, such as obesity, Parkinson's disease, addiction, metabolism and

antibiotics, to empower people to live healthier and more fulfilling lives.

What sets us apart is our deep-rooted commitment to understanding the needs and

requirements of the countries where we are present. Our local insight and

competence enable us to understand the specific needs of each country where we

operate and ultimately to gain market access. This makes us a preferred partner

for international companies expanding their footprint across the Nordics and

Benelux regions, through either in-licensing or out-licensing. Navamedic has

been listed on the Oslo Stock Exchange since 2006 (ticker: NAVA) and is

headquartered in Oslo, Norway. For more information, please visit

www.Navamedic.com

This information is subject to the disclosure requirements pursuant to Section 5

-12 the Norwegian Securities Trading Act.

AI Terminal